Drugs / rAAV-Olig001-ASPA
rAAV-Olig001-ASPA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04833907 | Apr 2021 → Aug 2026 overdue | Canavan disease | Myrtelle Inc. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV-Olig001-ASPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04833907 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “The latest generation AAV viral vector (rAAV-Olig001-ASPA) will be administered to patients using neurosurgical procedure which involves direct administration of gene therapy...” NCT04833907 ↗ |
| Route | Other | “delivered intracerebroventricularly” NCT04833907 ↗ |